Browsing by Author "Ayaz, C"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Management of Chronic Hepatitis D Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases
    (DOC DESIGN INFORMATICS CO LTD) Ayaz, C; Yardimci, C; Çandir, N; Ersöz, G; Sanlidag, T; Tigli, A; Türken, M
    Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases convened a meeting to develop a consensus report on management of chronic hepatitis D virus (HDV) infection, affecting nearly 5% of people infected with hepatitis B virus worldwide. Relevant literature and international guidelines were reviewed, and recommendations agreed are presented at the end of each section such as epidemiology, natural history and diagnosis of HDV infection, indications for treatment, treatment and follow-up, evaluation of response to treatment and long-term outcomes in HDV infection. Examples of some selected recommendations are as follows: [1] Patients with compensated liver disease, documented HDV viremia and elevated transaminase levels should be treated regardless of their liver histology. [2] Peg-IFN should be used for treatment of HDV infection. [3] Duration of therapy should be at least one year. [4] Treatment prolongation, provided that it can be tolerated, should be considered because of its potential benefit on virological response. [5] Although oral antivirals do not impact HDV replication, if they are needed to be used for HBV infection, a nucleotide analogue should be preferred to achieve a decline in HBsAg levels.
  • No Thumbnail Available
    Item
    Epidemiology and Risk Factors of Hepatitis Delta Infection in Turkey
    (DR M N KHAN) Ayaz, C; Koruk, ST; Yalci, A; Yamazhan, T; Aygen, B; Tosun, S; Dal, T; Celen, MK; Tabak, F
    This study is aimed to investigate the prevalence and risk factors of HDV co-infection in patients with chronic HBV infection in Turkey, where HBV infection is endemic. The date of this study was obtained from Turk-Hep-Net project. The project includes real-life cohort of HBV patients from 15 centers in Turkey and is supported by Viral Hepatitis Society. Of the 7366 HBsAg positive individuals tested for the presence of anti-HDV antibodies, 63,6 were male and 36.4 % were female. Of the 7366 HBsAg positif patients, 206 (2.8%) contained anti-HDV. Southeastern Anatolia Region of the country's anti-HDV positivity rate was found to be 4.5%. The risk factors in anti-HDV positivity patient were; male gender, long-term (>5 year) HBsAg positivity and living in Southeastern Anatolia. Our study revealed that recognizing the risk factors associated with HBV and HDV co-infection will be beneficial to control of these infections.